NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed James M. O’Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private ...

回顾：上周6只新股上市，共募资约5.4亿美元。 Off The Hook(OTH)以每股4美元，发行了375万股(原计划发行500万股)，募集了1500万美元。 Phaos Technology(POAS)以每股4美元，发行了360万股，募集了1440万美元。 Caring Brands(CABR)以每股4美元，发行了100万股，募集了400万美元。 SPAC Evolution Global Acquisition (EVOXU)、Blueport Acquisition (BPACU)、Alussa Energy Acquisition II (ALUBU)分别募集了2.1亿美元、5000万美元、2.5 亿美元。 此外，12家公司递交招股书，其中5家来自中国，含4家空白招股书(拟通过这种方式上市毫无可能)，另1家为客路(KLK)，详情请见：IPO速递丨客路赴美 IPO 拟纽交所上市 红杉、软银为股东 本周，暂有4家公司计划上市，如下： 1、专注于信仰的技术平台——Gloo Holdings, Inc. 股票代码：GLOO Gloo为信仰组织提供垂直一体化平台服务的公司，主要提供涵盖云服务、IT管理、网络安 ...

The after-hours session on Friday, November 14, 2025, brought notable moves across several biotech and therapeutics names, as corporate updates, financial results, and strategic announcements drove sharp price reactions. From acquisition agreements to pivotal trial milestones, these developments shaped trading momentum well beyond the regular market close.Repare Therapeutics Inc. (RPTX) surged in after-hours trading, closing at $2.15, up 30.32% or $0.50. The company announced that it has entered into a def ...

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen ...

JSPR DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPRNovember 16, 2025 9:38 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 16, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusiv ...

公司治理与股权变更 - 股东特别会议所有提案均获多数票通过 [1] - Faraday Future成为公司新的控股股东，直接持股约55%，连同关联股东YT Jia和Jerry Wang，总持股比例增至约63% [2] - Faraday Future将任命重组后董事会的大部分成员，治理结构调整将于公司计划更名前完成 [3] 战略转型与品牌重塑 - 公司将于2025年11月20日正式更名为AIxCrypto Holdings, Inc，并在纳斯达克举行更名及代码激活仪式，新交易代码为AIXC [4][10] - 此次品牌演变标志着公司从传统生物技术向Web3驱动的去中心化人工智能技术平台的战略转型 [5] - 更名象征着公司身份、商业模式、技术战略和生态系统定位的全面升级，公司明确转型为专注于去中心化AI、Web3资产基础设施和智能交易系统的跨学科技术企业 [6][8] 未来发展蓝图与活动 - 在11月20日的仪式上，公司将公布全新的业务框架、生态系统架构以及三年发展路线图，旨在将自身定位为AI × Web3时代的全球领先门户 [4][7][10] - 此次转型预计将在AIxCrypto与Faraday Future之间建立互惠的战略赋能动态，加速创新、生态系统整合和长期价值创造 [5] - 公司将进入与其技术、增长和资本市场战略相一致的新执行阶段 [12] 股东会议批准事项 - 根据纳斯达克规则5635(a)和(b)批准了认购协议，授权发行337,432股普通股和39,943股B系列可转换优先股 [11] - 批准根据规则5635(d)超过纳斯达克19.99%的发行门槛 [11] - 批准包含常青条款的2025年股权激励计划，以支持长期人才保留并与股东利益保持一致 [11]

CYTK DEADLINE: ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTKNovember 16, 2025 10:35 AM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 16, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Cl ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 16, 2025 ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Shares of respiratory disease concern Savara, Inc. ( SVRA ) have rebounded over 100% since receiving a refuse-to-file letter from the FDA for its sole clinical candidate (molgramostim) in May 2025. The rebound is largely due to the comp ...